Tellus Therapeutics, a company developing treatments for newborns in the neonatal intensive care unit (NICU), announced the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund. The capital will be used to continue preclinical work conducted through the seed investment with the Xontogeny development team and to […]
